Investigates the anti-infective properties of Murraya koenigii in Gram-negative bacteria, suggesting therapeutic potential.
Purpose To assess the antioxidant-rich fraction of Murraya koenigii for its anti-infective properties against Gram-negative pathogenic bacteria by in vitro and in silico approaches. Results The most antioxidant active fraction, i.e., M. koenigii chloroform fraction (MKCF), significantly reduced violacein production (70.73%) in Chromobacterium violaceum 12,472. Significant reduction in prodigiosin production, protease activity, and swarming motility of Serratia marcescens , and other tested virulence factors of Pseudomonas aeruginosa PAO1 was recorded. More than 60% reduction in biofilm formation was recorded against test pathogens, indicating broad-spectrum anti-infective activity. SEM and CLSM imaging revealed alterations in the structure of the biofilm. Major key compounds such as Gibberellic acid, methyl ester, 7,8-Epoxylanostan-11-ol, 3-acetoxy were detected by GC/MS, and numerous compounds in MKCF were identified using LC-qTOF/MS analysis. In silico analysis revealed morellin and murrayazolinol with good binding affinity with CviR and EsaI, with binding energies of −9.07 and −9.17 kcal mol −1 , respectively. Conclusion The most active antioxidant fraction, i.e., MKCF, could be exploited as an anti-infective agent against Gram-negative bacterial pathogens, attenuating virulence and pathogenicity. Further, in vivo efficacy of the active fraction/phytocompounds needs to be evaluated to explore the therapeutic potential of MKCF.
No takes yet. Share an insight, caveat, or question.
Haris et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: